Premium
Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation
Author(s) -
Rowe Dominic B.,
Le Weidong,
Smith R. Glenn,
Appel Stanley H.
Publication year - 1998
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/(sici)1097-4547(19980901)53:5<551::aid-jnr5>3.0.co;2-8
Subject(s) - dopamine , parkinson's disease , antibody , medicine , disease , chemistry , immunology
To determine whether specific antibodies are present in PD, we used an enzyme‐linked immunosorbant assay (ELISA) that identifies increased immunoglobulin (IgG) levels towards a synthetic substrate prepared by incubating ovalbumin with dopamine and copper sulfate. Altered absorption spectrum and specific chemical detection demonstrated quinone modification of the ovalbumin. This modified protein was demonstrated to react with serial dilutions of PD sera. A threshold dilution of 1:500 was subsequently used to screen sera from patients with PD (n = 21), amyotrophic lateral sclerosis (n = 7), Alzheimer's disease (n = 7) and other neurological disease controls (n = 7). The assay produced a positive result in 7/21 PD patients and 0/21 disease controls ( P < 0.02, Kruskal–Wallis test). Further testing of sera from untreated PD patients (n = 6) identified one positive sample. Thus, a subset of Parkinson's disease (PD) patients has immunoglobulin (IgG) to ovalbumin modified by dopamine oxidation. The presence of antibody reactivity to quinone‐modified proteins could contribute to or amplify the inflammatory response in PD. J. Neurosci. Res. 53:551–558, 1998. © 1998 Wiley‐Liss, Inc.